The difference is one receptor, and that receptor is the entire reason the two are compared. Both are also the most regulated compounds in this catalogue, which needs stating before anything else.
Regulatory position, first
Tirzepatide is an approved prescription medicine in the UK and elsewhere. Retatrutide is investigational and not approved anywhere.
Both are supplied here strictly as laboratory reagents for in vitro research. Neither is supplied for human use. Obtaining an approved prescription medicine outside a prescription is unlawful, and a research use declaration does not change that analysis.
If you are reading this looking for either compound for personal use, this is the wrong site and we will decline the order.
Receptor profiles
| Receptor | Tirzepatide | Retatrutide |
|---|---|---|
| GIP | Agonist | Agonist |
| GLP-1 | Agonist | Agonist |
| Glucagon | No activity | Agonist |
Tirzepatide is a dual agonist. Retatrutide adds glucagon receptor activity, making it a triple agonist. That is the whole distinction and everything else follows from it.
Why the third receptor is interesting
GIP and GLP-1 are incretin receptors. Glucagon acts on a different axis, and adding activity there is proposed to contribute through energy expenditure pathways rather than through the appetite pathways associated with GLP-1.
Whether that proposal holds, and at what balance of activities, is the open question that most receptor level work is addressing. Balancing three agonist activities is a harder design problem than balancing two.
Pharmacology
Tirzepatide shows higher relative affinity at GIP than at GLP-1 in binding assays, and biased signalling at the GLP-1 receptor favouring cAMP production over beta arrestin recruitment. It has completed full phase three trials, so the human dataset is extensive.
Retatrutide is in clinical development. Its receptor level characterisation is published, and the comparative work against dual agonists is where most current laboratory interest sits.
Practical differences
| Property | Tirzepatide | Retatrutide |
|---|---|---|
| Molecular weight | ~4814 Da | ~4731 Da |
| Development code | LY3298176 | LY3437943 |
| Vial sizes here | 30mg | 20mg, 40mg |
| Storage | Frozen, protected from light | Frozen, protected from light |
Both are large peptides. Reconstitute slowly, do not agitate, and give dissolution time rather than energy. The molecular weights are close enough that they are easy to confuse and different enough to matter in a molar calculation.
Running them side by side
The usual comparative design holds receptor and readout constant and varies the compound. If you are doing that, order both from the same supplier and ideally in the same order, so the batch handling history is identical. Batch to batch variation across two suppliers is an uncontrolled variable in a comparison study.
What this page will not tell you
Anything about dosing, administration or use in a person. Those questions belong to a prescriber and this is a laboratory supply catalogue. If that is what you came for, a registered pharmacy or your GP is the correct route, and going around it with research grade material is neither safe nor legal.